During the last session, Enlivex Therapeutics Ltd (NASDAQ:ENLV)’s traded shares were 0.39 million, with the beta value of the company hitting 0.78. At the end of the trading day, the stock’s price was $1.19, reflecting an intraday gain of 3.48% or $0.04. The 52-week high for the ENLV share is $4.59, that puts it down -285.71 from that peak though still a striking 31.93% gain since the share price plummeted to a 52-week low of $0.81. The company’s market capitalization is $26.17M, and the average trade volume was 132.93K shares over the past three months.
Enlivex Therapeutics Ltd (ENLV) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ENLV has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
Enlivex Therapeutics Ltd (NASDAQ:ENLV) trade information
Enlivex Therapeutics Ltd (ENLV) registered a 3.48% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.48% in intraday trading to $1.19, hitting a weekly high. The stock’s 5-day price performance is -0.83%, and it has moved by 8.18% in 30 days. Based on these gigs, the overall price performance for the year is -63.27%.
The consensus price target of analysts on Wall Street is $15, which implies an increase of 92.07% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15 and $15 respectively. As a result, ENLV is trading at a discount of -1160.5% off the target high and -1160.5% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 32.51%. While earnings are projected to return 10.77% in 2025.
ENLV Dividends
Enlivex Therapeutics Ltd is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 0.24 million shares, is of MORGAN STANLEY’s that is approximately 1.3077% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.35 million.
Data provided on Dec 31, 2024 indicates that Fidelity NASDAQ Composite Index Fund owns about 10.42 shares. This amounts to just over 0.06 percent of the company’s overall shares, with a $12399.0 market value.
